ALN-PCS02

ALN-PCS02 is an investigational RNA interference (RNAi) therapeutic developed for the treatment of hypercholesterolemia, specifically targeting elevated low-density lipoprotein cholesterol (LDL-C). It is a small interfering RNA (siRNA) molecule formulated in lipid nanoparticles for intravenous administration. The drug acts by silencing the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that regulates LDL receptor degradation and thus influences plasma LDL-C levels. By inhibiting PCSK9 synthesis in the liver, ALN-PCS02 leads to significant reductions in both circulating PCSK9 and LDL-C levels. In Phase 1 clinical trials, ALN-PCS02 demonstrated rapid, dose-dependent knockdown of plasma PCSK9 by up to 84% and corresponding reductions in serum LDL-C by up to 57%, with effects lasting for weeks after a single dose. The drug was well tolerated with no serious adverse events reported[1][2][3][5].